for a phase three trial of a lung cancer treatment.
While the drug compared well to a competitor on one endpoint, the data for overall survival was "not mature" and pointed toward to the results being not statistically significant, AstraZeneca said in a press release. The trial will continue, according to the company.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: MarketWatch - 🏆 3. / 97 続きを読む »
Recession will take shine off stocks' AI-fueled rally in H2: HSBCUS stocks face a painful rest of 2023 with a recession set to take the shine off the AI-fueled rally, HSBC says
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »